/NGM

NGM Stock - NGM Biopharmaceuticals, Inc.

Q: What is the analyst price target for NGM?

Analyst price target information is not currently available for NGM.

Q: What is NGM's market cap?

Market capitalization information is not currently available for NGM.

Healthcare|Biotechnology|NASDAQ

$1.54-1.28%

$0.02 (-1.28%) • Apr 4

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+971.4%upside

Target: $16.50

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for NGM

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.26

52W High$4.69

52W Low$0.60

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	$4.42M	$55.33M	$77.88M	$87.37M	$103.54M
Gross Profit	$2.20M	$49.35M	$69.98M	$-76,604,000	$-25,709,000
Gross Margin	49.7%	89.2%	89.9%	-87.7%	-24.8%
Operating Income	$-146,547,000	$-166,249,000	$-120,695,000	$-103,833,000	$-49,340,000
Net Income	$-142,375,000	$-159,085,000	$-113,826,000	$-93,993,000	$-28,498,000
Net Margin	-3223.3%	-287.5%	-146.2%	-107.6%	-27.5%
EPS	$-1.73	$-1.99	$-1.48	$-1.37	$-0.57

Company Overview

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

43%

Hold / Neutral

57%

Sell / Underperform

Analyst Consensus🔴 Bearish

3 Bullish4 Neutral/Bearish

Price Targets

$10

Average Target

↑ 533.1% Upside

Now

Low

$10

Average

$25

High

Based on 4 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
March 12th 2024	Raymond James	Downgrade	Market Perform	-
February 28th 2024	TD Cowen	Downgrade	Market Perform	-
February 27th 2024	Citigroup	Downgrade	Neutral	-
May 3rd 2023	Citigroup	Initiation	Buy	$6
October 18th 2022	Goldman	Downgrade	Neutral	$4← $29
October 18th 2022	Raymond James	Downgrade	Outperform	$4← $42
October 17th 2022	Jefferies	Downgrade	Hold	-
October 17th 2022	Piper Sandler	Downgrade	Neutral	-
July 20th 2022	Jefferies	Initiation	Buy	$25

Earnings History & Surprises

NGM

Beat Rate

60%

Last 20 quarters

Avg Surprise

+5.5%

EPS vs Estimate

Beats / Misses

12/6

2 met exactly

Latest EPS

$-0.58

Q2 2024

EPS Surprise History

Q3 22

-7.3%

$-0.59vs$-0.55

Q4 22

+3.3%

$-0.59vs$-0.61

Q1 23

+13.5%

$-0.45vs$-0.52

Q2 23

-11.5%

$-0.58vs$-0.52

Q3 23

0.0%

$-0.46vs$-0.46

Q4 23

+12.5%

$-0.35vs$-0.40

Q1 24

+10.8%

$-0.33vs$-0.37

Q2 24

-26.1%

$-0.58vs$-0.46

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2024	May 2, 2024	$-0.46	$-0.58	-26.1%	✗ MISS
Q1 2024	Mar 11, 2024	$-0.37	$-0.33	+10.8%	✓ BEAT
Q4 2023	Nov 2, 2023	$-0.40	$-0.35	+12.5%	✓ BEAT
Q3 2023	Aug 3, 2023	$-0.46	$-0.46	0.0%	= MET
Q2 2023	May 4, 2023	$-0.52	$-0.58	-11.5%	✗ MISS
Q1 2023	Feb 28, 2023	$-0.52	$-0.45	+13.5%	✓ BEAT
Q4 2022	Nov 3, 2022	$-0.61	$-0.59	+3.3%	✓ BEAT
Q3 2022	Aug 4, 2022	$-0.55	$-0.59	-7.3%	✗ MISS
Q2 2022	May 5, 2022	$-0.42	$-0.42	0.0%	= MET
Q1 2022	Mar 1, 2022	$-0.37	$-0.35	+5.4%	✓ BEAT
Q4 2021	Nov 4, 2021	$-0.38	$-0.37	+2.6%	✓ BEAT
Q3 2021	Aug 5, 2021	$-0.39	$-0.48	-23.1%	✗ MISS
Q2 2021	May 6, 2021	$-0.42	$-0.36	+14.3%	✓ BEAT
Q1 2021	Mar 4, 2021	$-0.47	$-0.40	+14.9%	✓ BEAT
Q4 2020	Nov 12, 2020	$-0.39	$-0.43	-10.3%	✗ MISS
Q3 2020	Aug 12, 2020	$-0.33	$-0.38	-15.2%	✗ MISS
Q2 2020	May 13, 2020	$-0.29	$-0.28	+3.4%	✓ BEAT
Q1 2020	Mar 17, 2020	$-0.34	$-0.24	+29.4%	✓ BEAT
Q4 2019	Nov 12, 2019	$-0.26	$-0.17	+34.6%	✓ BEAT
Q3 2019	Aug 12, 2019	$-0.31	$-0.13	+58.1%	✓ BEAT

Frequently Asked Questions about NGM

What is NGM's current stock price?

NGM Biopharmaceuticals, Inc. (NGM) is currently trading at $1.54 per share. The stock has moved -1.28% today.

What is the analyst price target for NGM?

The average analyst price target for NGM is $16.50, based on 1 analyst.

What sector is NGM Biopharmaceuticals, Inc. in?

NGM Biopharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is NGM's market cap?

NGM Biopharmaceuticals, Inc. has a market capitalization of $0.13 billion, making it a small-cap company.

Does NGM pay dividends?

No, NGM Biopharmaceuticals, Inc. does not currently pay a dividend to shareholders.